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Abstract
Recent data on the cell deregulation that occurs during the progression to cancer un‐
derlines the cooperation between genetic and epigenetic alterations leading to a ma‐
lignant phenotype. Unlike genetic alterations, the epigenetic changes do not affect the
DNA sequence of the genes, but determine the regulation of gene expression acting
upon the genome. Moreover, unlike genetic changes, epigenetic ones are reversible,
making them therapeutic targets in various conditions in general and in cancer dis‐
ease in particular. The term epigenetics includes a series of covalent modifications that
regulate the methylation pattern of DNA and posttranslational modifications of histo‐
nes. Gene expression can also be regulated at the posttranscriptional level by micro‐
RNAs (miRNAs), a family of small noncoding RNAs that inhibit the translation of
mRNA to protein. miRNAs can act as ‘oncomiRs’, as tumor suppressors, or both. In
this chapter, we will (1) summarize the current literature on the key processes respon‐
sible for epigenetic regulation: DNA methylation, histone modifications and posttran‐
scriptional gene regulation by miRNAs; (2) evaluate aberrant epigenetic modifications
as essential players in cancer progression; (3) establish the roles of microenvironment-
mediated epigenetic perturbations in the development of gynecological neoplasia; (4)
evaluate epigenetic factors involved in drug resistance.
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1. Introduction
1.1. Key processes responsible for epigenetic regulation
Epigenetics could be broadly defined as the sum of cellular and physiological trait variations
that are not caused by changes in the DNA sequence. Epigenetic mechanisms are essential for
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
the normal development and maintenance of tissue-specific gene expression patterns in
mammals. Disruption of epigenetic processes can lead to altered gene function resulting in
imprinting disorders, developmental abnormalities and cancer. The epigenetic mechanisms
that will be presented in this chapter are (1) DNA methylation, (2) chromatin and histone
modifications, and (3) regulatory noncoding RNAs.
1.1.1. DNA methylation
DNA methylation is a biochemical process characterized by the addition of a methyl group
especially at the C5 position of cytosine from CpG dinucleotides and is accomplished by two
classes of DNA methyltransferases involved in maintenance and de novo methylation [1]. CpG
dinucleotides are not randomly distributed across the human genome but are found in short
CpG-rich DNA sequences called ‘CpG islands.’ CpG islands are found in regions of large
repetitive sequences (e.g. centromeric repeats, retrotransposon elements, rDNA) [2, 3] and in
60% of human gene promoters [4]. Some CpG islands are methylated, whereas the majority of
them usually remain unmethylated during development and in differentiated tissues [5]. CpG
islands’ promoters become methylated during development (imprinted genes, chromosome
X inactivation) [2]. Another role of CpG island methylation is to silence noncoding DNA and
transposable DNA elements to prevent chromosomal instability by heavy methylation of
repetitive sequences [5]. DNA methylation leads to gene silencing by either preventing or
promoting the recruitment of regulatory proteins to DNA. Methylation of CpG islands can
block the access of transcription factors to the transcription sites [6, 7], or by recruiting methyl-
binding domain proteins (MBDs), which can mediate gene repression through interactions
with histone deacetylases (HDACs) [8, 9]. This epigenetic modification does not change the
DNA sequence, but enhances the stability and chromosome integrity and promotes genome
organization into transcriptionally active or silenced regions. DNA methylation at the whole
genome level provides a specific global methylation pattern [2, 10] that plays an important role
in regulating gene expression (e.g. development and cell-specific gene expression) in associa‐
tion with chromatin-associated proteins. The maintenance of a cell-specific methylation
pattern after every cellular DNA replication cycle provides a stable gene-silencing mechanism
that plays an important role in regulating gene expression. The maintenance methyltransferase
DNMT1 is responsible for copying DNA methylation patterns to the daughter strands during
DNA replication, whereas DNMT3a and DNMT3b are de novo methyltransferases that
establish the methylation patterns early in development [11]. DNMT3L, a homologous protein
to other DNMT3s, increases the ability of DNM3a and 3b to bind to DNA, stimulating their
activity. Some problems in the establishment of methylation biomarkers in gynecologic
cancers, especially in cervical cancer [12], come from the fact that: (1) the extent of methylation
across the various CpG sites in a promoter can be rather heterogeneous and consequently, the
assay outcome is likely to be influenced by the region of CpGs that is targeted; (2) the distinct
levels of background methylation due to differences in cell type composition between cervical
tissue samples that can contain substantial amounts of nonepithelial (stromal) cells and cervical
scrapings that are enriched in superficial epithelial cells. For this reason, the methylation
results obtained from tissue samples may not be directly extrapolated to cervical scrapings
[13]. In addition, while the methylation of tumor suppressor’ promoters is an early and
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frequent alteration in carcinogenesis [14] and, on the other hand, is widespread in the human
genome, only a subset of affected loci play critical roles in tumorigenesis [15]. CpG hyperme‐
thylation is gene- and cancer type–specific [16, 17, 18, 19], providing a useful signature for
tumor diagnosis and prognosis [18] that must be established accurately.
1.1.2. Covalent histone modifications
Mammalian genome represents a highly structured complex comprised of compacted DNA
and proteins that can adopt different three-dimensional conformations dependent of nuclear
context and biochemical changes present in the genome and at the histone level [20]. At first
glance, the chromatin is present in two forms: transcriptionally active euchromatin and more
condensed and transcriptionally inactive heterochromatin. In the genome, there are some
structural regions (such as centromeres) containing constitutive heterochromatin; others may
go through an open conformation to a compact one—optional heterochromatin. These
transitions, vital to the establishment of necessary transcriptional various models of embryonic
development, growth, and adult life, are under epigenetic control. Nucleosomes form the
repetitive fundamental units of the chromatin and are designed to pack the huge eukaryotic
genome in the nucleus (mammalian cells contain approximately 2 m of linear DNA wrapped
in a core size of 10 µm in diameter) [20]. The nucleosomes in turn are compacted and form the
chromosomes. The nucleosomal core consists of approximately 147 base pairs wrapped around
a histone octamer made up of two copies of the histones H2A, H2B, H3, and H4. Histone H1
(linker histone) and its isoforms are involved in chromatin compaction underlying nucleosome
condensation. Decondensed nucleosomes look like a bead wrapping a DNA molecule [21].
Histone covalent modifications (epigenetic changes) represent important regulatory elements
that influence chromatin interactions by structural changes either by electrostatic interactions
and recruitment of nonhistone proteins [22].
Histones can undergo a variety of posttranslational modifications at the N-terminus (like
acetylation, methylation, phosphorylation, sumoylation, ubiquitination, and ADP-ribosyla‐
tion) that can alter the DNA–histone interaction, with a major impact on chromatin structure
and key cellular processes such as transcription, replication, and repair [20]. The histone code
may be transient or stable. The mechanism of inheritance of this histone code is not fully
understood. The patterns of histone modifications are specific to each cell type and play a key
role in determining cellular identity [23, 24]. In contrast with stem cells, differentiated cells
acquire a more rigid chromatin structure, which is important for maintaining cell specialization
[23]. Epigenetic regulation mediated by histone modification is a dynamic process. Lysine
residue methylation using histone methyltransferase (HMT) is correlated either with tran‐
scriptional activation or repression, whereas lysine acetylation correlates with transcriptional
activation [25]. Histone methyltransferases (HMTs) and demethylases (HDMs) work in
tandem to determine the degree of methylation of the lysine residue [26]. Histone H3 lysine 4
trimethylation (H3K4me3) correlates with euchromatin and gene transcription activation.
Histone H3 lysine 27 trimethylation and/or lysine 9 (H3K27me3/H3K9me3) is correlated with
the transcriptional repression of heterochromatin and H3K27me3 modification is critical for
stem cells; demethylation at this level is correlated with differentiation [27, 28, 29, 30, 31]. These
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two modifications represent the main silencing mechanisms in mammalian cells, H3K9me3
working in concert with DNA methylation and H3K27me3 largely working exclusive of DNA
methylation [32]. Histone acetylation is one of the histone modifications that have been studied
extensively. The two homonymous enzymes that are involved in maintaining a specific profile
are histone acetyltransferases (HATs) and histone deacetylases (HDACs) [26]. Generally, the
level of histone acetylation correlated with transcriptional activation and deacetylation
correlates with transcriptional repression. H3 histone acetylations at lysine 9 (H3K9ac) and
lysine 4 to 16 are characteristic euchromatin changes located in regions where genes are
actively transcribed. Although histone modifications act mainly by altering the architecture of
some modifications (H3K4me3 and H3K9ac) mediates gene regulation by recruiting other
proteins involved in chromatin remodeling [33, 34]. Histone modifications and DNA methyl‐
ation interact with each other at multiple levels to determine gene expression status, chromatin
organization, and cellular identity [35]. Several HMTs, including G9a, SUV39H1, and PRMT5,
methylate DNA to specific genomic targets recruiting DNA methyltransferases (DNMTs) [36,
37, 38]. In addition, DNMTs may recruit HDACs and methyl-binding proteins to achieve gene
silencing and chromatin condensation [8, 9]. DNA methylation can also be established via
H3K9 methylation, such as MeCP2, thereby establishing a repressive chromatin state [39].
Recent studies showed that the main chromatin changes that occurs during tumorigenesis are
characterized by a global loss of acetylated H4 lysine 16 (H4K16ac) and H4 lysine 20 trime‐
thylation (H4K20me3) [40]. HDACs were found overexpressed in various types of cancer [41,
42] (becoming a major target for epigenetic therapy), along with HATs, whose expression can
also be altered in cancer. MOZ, MORF, CBP, and p300 (HATs) may be targets for chromosomal
translocations, especially in leukemia [43]. Changes in histone methylation patterns (deregu‐
lation of HMTs) are associated with aberrant gene silencing in cancer, and an effective cancer
treatment strategy targeting HDMs represents a promising treatment option.
1.2. Posttranscriptional gene regulation by noncoding RNAs
Noncoding RNAs are involved in fundamental processes, such as chromatin dynamics and
gene silencing, and their transcripts outnumber the group of protein transcripts. It is well
known that the initiation of X-chromosome inactivation is regulated by noncoding RNAs (Xist
function) and the noncoding RNAs molecules are also involved in imprinting, suggesting that
antisense RNA can induce transcriptional silencing [44, 45, 46]. The characterized noncoding
RNA family consists of a large group of small regulatory microRNAs (about 1400 microRNAs
in humans) [47].MicroRNAs (miRNAs) are short noncoding RNAs of 20–24 nucleotides that
play important roles in virtually all biological pathways in mammals like differentiation and
growth control. Based on computer predictions, it was proposed that miRNAs may regulate
many cell cycle control genes [48]. miRNAs influence numerous cancer-relevant processes
such as proliferation, cell cycle control, apoptosis, differentiation, migration, and metabolism.
The key processes of miRNA biogenesis pathways have been characterized. Primary miRNA
transcripts are transcribed from separate transcriptional units or embedded within the introns
of protein coding genes by RNA polymerase II. Primary miRNA transcripts are processed by
a complex formed by RNase III enzyme and Drosha, resulting in a pre-miRNA hairpin that is
subsequently exported from the nucleus to the cytoplasm by exportin 5 (XPO5). Further pre-
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miRNA molecules are processed by another protein complex, including DICER and TRBP, to
produce the single-stranded mature miRNA (ssmiRNA). ssmiRNA is subsequently incorpo‐
rated in RNA induced silencing complex (RISC), along with key proteins such as AGO2 and
GW182. The role of mature miRNA (as part of the RISC) is to induce posttranscriptional gene
silencing by complementary sequence motifs to the target mRNAs predominantly found
within the 3′ untranslated regions (UTRs) [47, 49, 50]. One specific miRNA may target up to
several hundred mRNAs; therefore, a miRNA may silence various genes while a specific
mRNA may be targeted by several miRNAs. Aberrant miRNA expression may interfere with
gene transcription and influence cancer-related signaling pathways [51, 52, 53].New data are
added to decipher the role of miRNAs in normal physiology and pathology. Several microar‐
ray expression studies performed on a wide spectrum of cancer types have proved that
deregulated miRNAs expression is the rule rather than the exception in cancer [54, 55, 56, 57].
Animal models featuring miRNA overexpression or knock-down have demonstrated the
relation between miRNAs and cancer development, thus proposing miRNAs as potential
biomarkers and putative therapeutic targets [58]. In addition, since miRNAs were discovered,
many researchers focused their interest on identifying miRNAs generated by viruses. Several
data support this hypothesis mainly based on miRNA size, which allows them to avoid the
immune system but also to be supported by the small size of viral genome. It is not unexpected
that many miRNAs encoded by viruses have been discovered, most of them transcribed from
double-stranded DNA viruses [59]. miRNAs can regulate the expression of viral genes that
are involved in controlling viral replication. It is supposed that these miRNAs might influence
viral gene expression in a differentiation-dependent manner by targeting viral transcripts. On
the other hand, different hrHPV types have different oncogenic potentials, viral miRNA being
considered one of the factors involved in oncogenic regulation; some conserved miRNAs are
involved in the switch from HPV productive to transforming infections.
2. Evaluation of aberrant epigenetic modifications as essential players in
cancer progression
Normally, evolution and morphological state of genital organs are in close interdependence
with hormonal status that is different in different periods: childhood, sexual maturity,
climacterium, and menopause. On the other hand, there is an increasing interest in the
identification of diagnostic biomarkers and biomarkers able to predict both response to
treatment and survival. For an optimal planning of therapeutic strategy in high-risk patients,
a close association between biological variables and (epi)genetic profiles associated with
aggressive clinical behavior could be useful. Therefore, many cellular changes should be
analysed in this context.
Benign tumors of the vulva can be developed from epithelial components (papillomas and warts)
mezenchimatos tissue (fibroma, leiomyoma, lipoma, hemangioma, and lymphangioma), and
local glands (Bartholin gland cysts or cysts of sweat glands). Vulvar cancer is a rare malignant
disease accounting for less than 5% of gynecological malignancies [60, 61, 62]. The most
common vulvar cancers are epidermoid carcinoma and rarely adenocarcinomas that are
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developed in the Bartholin glands or sweat glands. Approximately 20%–40% of vulvar
squamous carcinomas are often associated with papilloma virus infection [60 - 66] and are
more frequent in young people. Non-HPV vulvar cancers occur in the elderly and are associ‐
ated with somatic mutations, especially in TP53 [60 - 63, 65, 66]. Tumors harbouring a mutation
have a worse prognosis than vulvar squamous cancers without (epi)genetic changes [67 - 70].
However, allelic imbalances seem to occur in both groups and the cumulative number of
epigenetic changes increases from dysplasia to cancer [71]. The data with respect to epigenetic
changes in vulvar cancer progression is limited to a few articles on DNA hypermethylation
but not to chromatin remodeling or histone modifications. This data is presented in Table 1.
Hypermethylation seems to be more frequent in vulvar squamous cancers than in vulvar
intraepithelial neoplasia, but more studies are needed. Taking into account the existence of
two etiological categories of vulvar carcinomas (related or not to HPV), the miRNA signature
in these two types of vulvar carcinomas were evaluated [72]. Some miRNAs had lower
expression in HPV-positive tumors (miR-1291, miR-342-3p, miR-193a-5p, miR-29c#-,
miR-106b#, miR-22#, miR-365, miR-151-5P, miR-144#, miR-125b-1#, miR-519b-3p, miR-26b,
miR-19b-1, and miR-1254) and other microRNAs had higher expression in HPV-positive
tumors (miR-1274B, miR-142-3p, miR-21, miR-708, miR-16, miR-660, miR-29c, miR-1267,
miR-454, and miR-186) [72]. In HPV-negative samples, we observed an association between
lymph node metastases with decreased expression of miR-223-5p and miR-19b-1-5p, vascular
invasion with decreased expression of miR-100-3p and miR-19b-5p-1, and advanced tumor
staging (FIGO IIIA, IIIB, and IIIC) with expression of microRNAs miR-519b-1-5p and
miR-133a. In addition, de Melo Maia and collaborators (2013) built a network between miRNA
expression profiles and putative target mRNAs (TP53, RB, PTEN, and EGFR) based on
prediction algorithms, demonstrating that the evaluated miRNAs can be involved in vulvar
cancer progression, thereby providing biomarkers for the establishment of prognostic and
predictive values of response to novel targeting therapies in vulvar cancer [72].
The vagina is a fibromuscular tubular organ, which histologically consists of three layers of
tissue: (1) an outer layer consisting of fibro-elastic connective tissue; (2) vaginal muscles with
a longitudinal outer layer and an inner layer of fibers circularly arranged in a spiral; and (3)
Malpighian mucosa, covered by squamous epithelium. The vaginal epithelium undergoes
changes in relation to the period of the woman’s life and depending on hormonal stimulus.
Histological changes are reflected in vaginal cytology. Vaginal epithelium responds to ovarian
stimuli through proliferation, differentiation and desquamation. Thus, in adult women, under
the action of estrogen during the proliferative phase, vaginal mucosa proliferates and differ‐
entiates morphologically and functionally, and later, during the luteal phase, under the action
of progesterone, superficial cell layer desquamation occurs. The action of estrogen on the
vaginal mucosa is exercised on the epithelium as well as on the subjacent stroma.
Vaginal cancer is also a rare malignancy, accounting for about 2%–3% of all gynecologic cancers
[73, 74]. The squamous cell carcinomas (SCC) are more frequent (80%–90%) than adenocarci‐
nomas. If the risk factors linked to vaginal squamous cell carcinoma are smoking, immuno‐
suppression, high number of sexual partners, papillomavirus and history of cervical
precancerous and cancerous lesions [75, 76, 77], in the case of the vaginal adenocarcinomas,
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particularly clear cell adenocarcinomas, exposure to an antiabortive drug diethylstilbestrol
(DES) was incriminated [78, 79, 80]. On the other hand, if squamous vaginal cancer tends to
occur more commonly in the proximal third of the vagina, especially the posterior vaginal
wall, the adenocarcinomas are mostly seen in the anterior upper vaginal wall [74]. Human
papillomaviruses have been also linked to vaginal cancers, HPV prevalence in 2/3 lesions of
vaginal intraepithelial neoplasia and invasive vaginal cancer being over 90% and 70%,
respectively [81, 82]. The HPV oncogenic transformation has been associated with high levels
of E6 and E7 viral oncoproteins in the epithelia that can be achieved by two mechanisms: (1)
increased production of E6 and E7 after the loss of E2 (the normal regulator of E6 and E7
expression) during viral integration [83]; (2) methylation of the E2-binding sites (E2BS) in the
viral LCR in the region close to the early promoter that could inhibit E6 and E7 transcription
[84]. Therefore, HPV16-related integration, methylation in E2BS3 and 4, and viral load may
represent different viral characteristics driving vaginal and vulvar carcinogenesis [85].The
adverse health outcomes induced by DES exposure during fetal development include infer‐
tility, early menopause, and breast cancer, along with a rare form of vaginal adenocarcinoma
in adolescent girls [86, 87]. While animal models show an association of early exposure to
estrogens with the expression levels of several genes [88, 89, 90] and epigenetic changes,
including DNA methylation and histone modifications [91, 92, 93], the first study that evaluates
the possible effects of in utero DES exposure on genome wide DNA methylation in humans
cannot find evidence of large persistent effects of in utero DES exposure on blood DNA
methylation [94].
The uterus is a hollow organ, in which the product of conception is developed. It consists of
three parts: body, isthmus, and cervix. The corpus presents a mucosa (endometrium), muscular
wall (myometrium), and serous peritoneal surface. The endometrium is a specialized tissue,
particularly receptive to the influence of sex hormones that differs from a histological point of
view at prepubertal periods, sexual maturity, and menopause. Also, the uterine mucosa is in
constant transformation during menstrual cycles, sexual maturity, growth processes, func‐
tional maturation, and regression. Similar risk factors for endometrial cancers were incrimi‐
nated: adult obesity [95], first-degree family history of endometrial cancer, or colorectal cancer
[96]. Nulliparity and infertility appeared to independently contribute to endometrial cancer
risk [97]. The endometrium is extremely sensitive to hormones, the estrogen and progesterone
being two key regulators of proliferation and differentiation in reproductive tissues [98]. The
two isoforms of the progesterone receptor, PRA and PRB, required for endometrial differen‐
tiation [99], are generated by alternative transcription and translation from the same gene with
the addition of 164 amino acids in the N-terminus sequences of PRB [98] that makes them
functionally different [99]. A shift in the estrogen–progesterone balance is the major cause for
the development of endometrial cancer [100]. Progesterone is an important inducer of
endometrial differentiation and an inhibitor of tumorigenesis because the addition of progestin
(synthetic progesterone) can prevent endometrial cancer induced by an excess of estrogens
from endogenous sources (e.g., adipose tissue storage of estrogen and with polycystic ovarian
syndrome) or from exogenous sources in therapeutic administration [100]. While progestin
therapy achieves promising outcomes with early stage endometrial cancer, advanced and
recurrent disease has only minor effects. This is due to the fact that in advanced endometrial
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cancer, the progesterone receptor is lost but it has been demonstrated that reestablishing
progesterone signaling in these cells can inhibit endometrial cancer cell proliferation and
invasion and increase sensitivity to apoptotic stimuli [100]. The epigenetic restoration of
progesterone receptor expression could result in resensitization of endometrial tumors to
progestin therapy. The functional role of epigenetic factors in endometrial cancer development
began to be evaluated. A study by Jones and collaborators (2013) emphasizes the role of
HAND2 hypermethylation, which is a key step in endometrial carcinogenesis [101]. HAND2
is a basic helix-loop-helix transcription factor and developmental regulator [102], expressed in
the normal endometrial stroma. The physiological function of HAND2 is to suppress the
production of fibroblast growth factors that mediate the paracrine mitogenic effects of estrogen
on the endometrial epithelium [103]. HAND2 is under progesterone regulation [104, 105],
entering in the progesterone-mediated suppression of estrogen-induced pathways. Conse‐
quently, the methylation of HAND2 is able to predict the response to progesterone [101].
HAND2 methylation is the most common molecular alteration in endometrial cancer and, on
the other hand, is an early event in endometrial carcinogenesis that makes it a sensitive test to
correctly identify endometrial cancer patients amongst those women who present with
postmenopausal bleeding [101].
Histologically, the cervix shows mucosa, muscle wall, and the peritoneal serosa. The mucosa
of the cervix has an exocervical portion (covered by squamous epithelium, nonkeratinized)
and one endocervical (covered by a single-layered cylindrical epithelium, mucus secreting,
which contains a small number of ciliated cells, basal stem cells and racemic, tubular, or
branched type glands). Cancer of the uterine cervix is the major cause of death from gyneco‐
logical cancers and in over 90% of cases is associated with high-risk human papilloma virus
(hrHPV). Etiological factors include cigarette smoking, impairment of cell-mediated immun‐
ity, and long-term estrogen–progestin use [106, 107, 108]. But the main etiological factor of
squamous cell carcinoma (that accounts for about 80% of the cases) as well as adenocarcinoma
are human papilloma virus infections [109]. The role of other sexually transmitted infections
(Chlamydia trachomatis and herpes simplex virus) is still unclear [108, 110].In cervical cancer,
tumorigenesis of both squamous cell carcinoma and adenocarcinoma is HPV-related [109].
The transforming potential of E6 and E7 viral oncoproteins is based on their numerous actions
on cellular proteins, mainly on p53 and pRB tumor suppressors, which are degraded and
inactivated, respectively. In addition to the already reported genomic alterations in cervical
cancer development by hrHPV, many studies underline the involvement of epigenetic
alteration in host cell genes or at the levels of RNA. In order to find some diagnostic and
prognostic biomarkers, the methylation of host cell genes and methylation of viral genes were
evaluated [12]. The CpG hypermethylation of promoters of tumor suppressor genes, an early
and frequent alteration in carcinogenesis, affects all important pathways: cell adhesion (cell
adhesion molecule 1 (CADM1)) [13], E-cadherin [111, 112], apoptosis (DAPK, a proapoptotic
serine/threonine kinase [113, 114]), cell cycle (cyclin A1 methylation [114, 115]), fragile histidine
triad (FHIT) [116], cell signaling pathways (retinoic acid receptor [117], Ras association domain
family 1 isoform A (RASSF1) [118]), Wnt/β catenin pathway (adenomatous polyposis coli
(APC) [119] and PTEN [120]), p53 signaling pathway (p73 [121]), and DNA repair (O6
methylguanine DNA methyltransferase (MGMT) [113, 122]).For cervical scrapings, some
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methylation marker panels of host genes, with sensitivities of over 80% for CIN3+ were
evaluated: SOX1/PAX1, SOX1/LMX1A, SOX1/NKX6-1, PAX1/LMX1A; PAX1/NKX6-1,
LMX1A/NKX6-1 [123], JAM3/EPB41L3/TERT/C13ORF18 [124], and CADM1/MAL [13, 125],
etc. Host gene methylation analysis might be an alternative for hrHPV DNA detection because
aberrant methylation can be detected in cervical smears up to 7 years prior to the diagnosis of
cervical cancer [126]. On the other hand, for methylation analysis, cervical scrape samples as
well as self-collected cervico-vaginal lavage samples can be used [127].As accurate predictor
tests, the measurement of DNA methylation in HPV genomes, in certain early (E) and late (L)
open reading frames (ORF) as well as in parts of the upstream regulatory region (URR), may
have diagnostic value. The hypermethylation in the L1 region was a common feature of cervical
cancer but not of CIN induced by HPV16 [128], or HPV18 [129]. But the DNA methylation on
multiple CG sites in the L1, L2, E2, and E4 ORFs were significantly associated with CIN2+ after
accounting for multiple testing [130]. Some studies have contradictory results because most
were quite small and heterogeneous and did not always include (1) comparable sets of
specimens (cancer, high-grade CIN, cell lines), (2) exactly the same CG sites, or (3) the same
methodology [12]. Overall, as cervical cancer prevention moves to DNA testing methods,
DNA-based biomarkers, such as HPV methylation could serve as a reflex strategy to identify
women at high risk for cervical cancer [131], but the region with the best predictive value must
be established.In addition to the already reported genomic alterations in cervical cancer
development by hrHPV, many studies underline the involvement of viral or cellular miRNAs,
mainly based on the fact that some RNA micromolecules target transcriptional factors that
modulate both cellular and viral gene expression [132, 133].In HPV infection, E6 decreases
miR-34a [132, 134], which is a target of p53, thus the effect of E6 on miRNA-34a is mediated
by decreased p53 [132,134]. On the other hand, one of the targets of miR-34a is p18Ink4c [135],
an inhibitor of CDK4/6 that promotes the cell cycle. E7 decreases miR-203 during keratinocyte
differentiation, which is a tumor suppressor and thus increases carcinogenesis [136] through
an increase of cell survival targeting antiapoptotic protein bcl-w [137], induction of G1 cell
cycle arrest targeting survivin [138], inhibition of migration and invasion targeting LIM and
SH3 protein [139]. E7 upregulates miR-15a, miR-15b, and miR-15b through E2F1 and E2F3
[140, 141] and in turn, these miR decrease cyclin E1, leading to cell cycle arrest [142]. A lot of
other miRs are upregulated or decreased by virus oncogenes inducing changes in cellular
signaling pathways, some of these have not yet been elucidated [143].
Ovaries, paired organs, constitute the female sexual gland with endocrine lunette and also
produce ova. The ovary is covered by germinal epithelium (formed from cuboid or cylindrical
cells) and subjacent is a thin layer of dense connective tissue. The ovary presents a cortical area
(comprised of follicles, corpus luteum, and stroma) and a medulla. Starting from puberty till
menopause, there is a growth and maturation of one ovarian follicle during each menstrual
cycle and the formation of one corpus luteum after rupture of the follicle and oocyte removal.
If the egg is not fertilized, the corpus luteum regresses, undergoes progressive sclerosis
forming a hyaline. If the egg is fertilized, the corpus luteum becomes more voluminous and
luteal cells increase, constituting the corpus luteum of pregnancy. Ovarian stroma is formed
from fibroblastic and mesenchymal cells. Stromal cells present both characters of connective
cells and steroid activity (secreting androgens and estrogens). Ovarian medulla consists of lax
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connective tissue containing blood and lymph vessels, nerves, and embryonic elements. The
growth and development of the follicle during the ovarian cycle are driven by two gonado‐
trophic hormones, secreted by the anterior pituitary: follicle-stimulating hormone (FSH) and
luteinising hormone (LH). Both FSH and LH are under the control of gonadotrophin-releasing
hormone (GnRH) secreted by the hypothalamus through negative feedback carried out by
estrogens that are secreted by thecal cells of the follicle.
Ovarian cancer ranks second after cervical cancer worldwide. On the other hand, ovarian
cancer is in seventh place in terms of incidence among malignant tumors in women and eighth
with respect to death due to malignant tumors in women worldwide [144]. If approximately
90% of ovarian cancers arise from epithelial cells, 3% are from germ cells and 7% from
granulosa-theca cells. Ovarian cancer comprises different types of tumors with widely
differing clinicopathologic features and behaviors. Based on clinicopathologic and molecular
genetic studies, two histologic types of epithelial ovarian serous carcinomas were established:
low-grade serous carcinomas (LGSCs) and high-grade serous carcinomas (HGSCs) [145].
Although they are developed independently along different molecular pathways, both types
develop from fallopian tube epithelium and involve the ovary secondarily. Type I tumors
(LGSCs) are comprised of low-grade serous, low-grade endometrioid, mucinous, and clear cell
carcinomas; typically present as large cystic masses confined to one ovary; have a relatively
indolent course; and are relatively genetically stable being associated with mutations in KRAS,
BRAF, PTEN, PIK3CA, CTNNB1, ARID1A, and PPP2R1A [146, 147] that perturb signaling
pathways. Type II tumors (HGSCs) are composed of high-grade serous, high-grade endome‐
trioid, undifferentiated carcinomas and malignant-mixed mesodermal tumors; clinically
aggressive and typically present at an advanced stage, which contributes to their high fatality
[148]; at the time of diagnosis, they demonstrate marked chromosomal aberrations but over
the course of the disease these changes remain relatively stable [149]; approximately 60% of
HGSC have the fallopian tube as the origin of serous tumors [150], because the expression
profiles of ovarian HGSCs more closely resemble fallopian tube epithelium than the ovarian
surface epithelium [151]; they harbor TP53 mutations in over 95% of cases [152, 153], but rarely
harbor the mutations detected in the low-grade serous tumors; another possible origin of
HGSC is from inclusion cysts through a process of implantation of tubal (müllerian-type) tissue
rather than by a process of metaplasia from ovarian surface epithelium (mesothelial). Hyper‐
methylation has been found to be associated with the inactivation of almost every pathway
involved in ovarian cancer development, including DNA repair, cell cycle regulation, apop‐
tosis, cell adherence, and detoxification pathways [154]. Complete or partial inactivation of the
BRCA1 gene through hypermethylation of its promoter has been reported in 15% of sporadic
ovarian tumors [155, 156], 31% of carcinomas but not in the benign or borderline tumors [157],
or in the hereditary type of the disease, nor in samples from women with a germ line BRCA1
mutation [158, 159]. On the other hand, hypermethylation of BRCA1 was detected at a
significantly higher frequency in serous carcinomas than in tumors of the other histological
types [160]. The homeobox genes (HOX), a family of transcription factors that function during
embryonic development and control pattern formation, differentiation, and proliferation [161]
was associated with ovarian cancers [162]. In addition, based on the high percentage of
methylation of the HOXA9 gene observed in 95% of patients with high-grade serous ovarian
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carcinoma [163, 164], it has been suggested that the methylation status of HOXA9 and
HOXAD11 genes may serve as potential diagnostic and prognostic biomarkers [163,164]. Some
other genes found hypomethylated were associated with progression towards cancer: LINE-1
elements [165], SNGG (synucelin-γ), encoding an activator of the MAPK and Elk-1 signaling
cascades [166, 167], etc. Overall, DNA hypomethylation may promote tumorigenesis by
transcriptional activation of proto-oncogenes and on the other hand loss of imprinting or
genomic instability. DNA hypermethylation predisposes to gene mutation because the
methylated cytosines are often deaminated and converted to thymine leading to inactivation
of tumor suppressor genes. However, these phenomena deregulate the main functions of
gynecological cancer cells (Figure 1 and Table 1).
Figure 1. Biological functions influenced by alterations of DNA methylation in gynecological cancers.
Genes Functions Expression change Epigenetic regulation References
Ov
ari
an
 ca
nce
r BRCA2 Cell proliferation and differentiation Overexpression Hypomethylation 168, 169
CLDN3;CLDN4 Migration and invasion Overexpression
DNA
hypomethylation, H3
acetylation; Loss of
repressive histone
modifications
170, 171, 172
Interplay of Epigenetics with Gynecological Cancer
http://dx.doi.org/10.5772/61032
25
Genes Functions Expression change Epigenetic regulation References
HOXA10
HOXA11
Fertility, embryo viability,
regulation of hematopoietic lineage
commitment; regulation of uterine
development and is required for
female fertility
Overexpression
DNA
hypomethylation/
hypermethylation
164, 173, 174,
175
MAL
Formation, stabilization and
maintenance of glycosphingolipid-
enriched membrane microdomains
Overexpression Hypomethylation 176
NFKB1
Cell proliferation; Inflammation,
immunity, differentiation, cell
growth, tumorigenesis, and
apoptosis
Overexpression miR-9 downregulation177
SNCG Cell proliferation Overexpression DNAhypomethylation 167
BMI1 Cell proliferation Overexpression miR-15a and miR-16down regulation 178
TUBB3 Taxane drug resistance Overexpression
DNA
hypomethylation,
chromatin acetylation
179
ARID3B
Epithelial-to-mesenchymal
transition; Embryonic patterning,
cell lineage gene regulation, cell
cycle control, transcriptional
regulation and possibly in chromatin
structure modification
Overexpression
miR-125a
downregulation via
EGFR signaling
180
BCL3 Cell proliferation, tumorigenesis Overexpression miR-125bdownregulation 181
BRCA1
DNA repair, cell cycle checkpoint
control, and maintenance of
genomic stability
Overexpression Hypermethylation 182
PTEN, p14ARF Cell cycle regulation Overexpression Hypermethylation 182
DAPK Regulator of programmed cell death Overexpression Hypermethylation 182
RASSF1A
Negative regulator of cell
proliferation through inhibition of
G1/S-phase progression
Overexpression Hypermethylation 159,182, 183
p16INK4A Cell cycle regulation Overexpression Hypermethylation 183
APC Tumor suppression by antagonizingthe WNT. Overexpression Hypermethylation 159, 183
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Genes Functions Expression change Epigenetic regulation References
CTGF Cell adhesion, migration,proliferation, angiogenesis Overexpression Hypermethylation 184
CCBE1 Extracellular matrix remodeling andmigration Overexpression Hypermethylation 185
HIC1 Transcription factor Overexpression Hypermethylation 159
RARb Cell differentiation Overexpression Hypermethylation 183
E-cadherin Cell adhesion Hypermethylation 183
H-cadherin Regulation of cell growth, survivaland proliferation Overexpression Hypermethylation 183
hMLH1
Regulation of cell growth, survival
and proliferation
DNA mismatch repair
Overexpression Hypermethylation 186, 187, 188
GSTP1 Detoxification Overexpression Hypermethylation 189
MGMT Potential prognostic cancer Overexpression Hypermethylation 187,188
CYP39A1 Potential prognostic cancer Overexpression Hypermethylation 190
GTF2A1,
FOXD4L4, EBP Potential prognostic cancer Overexpression Hypermethylation 190
HAAO Potential prognostic cancer Overexpression Hypermethylation 190
En
do
me
tria
l ca
nce
r BMP2,3,4,7 Cell growth and EMT Overexpression Hypomethylation 191
SOX4 Prognosis Overexpression
miR-129-2
downregulation by
DNA
hypermethylation
192
hMLH1
Regulation of cell growth, survival
and proliferation; DNA mismatch
repair
Hypermethylation 193, 194
RASSF1A
Negative regulator of cell
proliferation through inhibition of
G1/S-phase progression
Hypermethylation 195, 196, 197
CHFR Regulates progression of the cellcycle Hypermethylation 198, 199
APC Signaling and intracellular adhesion Hypermethylation 200
THBS2 Inhibitor of tumor growth andangiogenesis Hypermethylation 201
p16INK4A Cell cycle regulation Hypermethylation 202
PTEN Cell cycle regulation Hypermethylation 203
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Genes Functions Expression change Epigenetic regulation References
PER1 Cells circadian rhythmsmaintenance; cancer development Hypermethylation 204
HOPX Tumorigenesis Hypermethylation 205
CDH13 Regulation of cell growth, survivaland proliferation Hypermethylation 206
HSPA2, MLH1 Regulation of cell growth Hypermethylation 206
SOCS2 Cytokine-inducible negativeregulators of cytokine signaling Hypermethylation 206
PAX2 Transcriptional factor Hypomethylation 207
Vu
lva
r c
an
cer CDKN2A Cell cycle regulation Hypermethylation 208, 209
MGMT Potential prognostic cancer Hypermethylation 210
RASSF2A Tumor suppressor gene Hypermethylation 210
RASSF1A
Negative regulator of cell
proliferation through inhibition of
G1/S-phase progression
Hypermethylation 210
TERT Cellular senescence Hypermethylation 209
TSP1 Platelet aggregation, angiogenesis,and tumorigenesis Hypermethylation 210
TFPI2 Tumor suppressor gene Hypermethylation 209
TP73, FHIT Cell cycle regulation; apoptosis Hypermethylation 211
TSLC-1 Hypermethylation 212
Ce
rvi
cal
 ca
nce
r CAGE RNA processing Overexpression Hypomethylation 213
MAP2K3 Cell proliferation Overexpression miR-214downregulation 177
MAPK8 Cell proliferation Overexpression miR-214downregulation 177
PTGS2 Cell proliferation, migration,invasion Overexpression
miR-101
downregulation 214
SERPINH1 Metastasis Overexpression miR-29adownregulation 215
VEGFA Tumor growth, angiogenesis Overexpression
miR-203
downregulation by
DNA
hypermethylation
216
Table 1. Altered DNA methylation in gynecological cancer
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miRNA as key players in cell fate decisions are strongly linked to gynecological cancer. But,
although the methods to discover miRNA were improved, research is still in progress. Some
of these miRNA that have been associated with gynecologic cancers are shown in Figure 2 and
Table 2.
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Figure 2. Venn diagram showing dysregulated miRNAs in gynecological cancers. (A) miRNAs downregulated, (B)
miRNAs upregulated. Common miRNAs dysregulated signature between ovarian and other cancers are shown in red.
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Specific miRNAs have effects on various molecular pathways, and specific miRNA expression
signatures in gynecological cancers can be associated with diagnosis, prognosis, and therapy
response. miRNAs can regulate a large number of target genes and Table 2 lists the estimated
targets.
miRNA(s)
Expression
(Up/
downregulat
ed)
Estimated target(s) References
Ov
ari
an
 ca
nce
r
Let-7a,b, c, d, e, f, g Down c-Myc, KRAS, HMGA2, IL-6, LIN28B, HIC2 217, 218
Let-7i Down HMGA2, LIN28Bm TRIM71,IGF2BP1 219
1 Down FOXP1, HDAC4 c-Met, Pim1, HAND2 220
9 Down NF-kB, Bcl2, Bcl6, FGF, b-Raf 220, 221
15a, 16 Down BMI1 178
21 Down PTEN 222
30b,d Down Unknown 223, 224
34a,b,c Down SIRT1, MYC, NOTCH, BCL2, CCND1,WNT3 222, 223, 225
95 Down AIB1, GNAI2 226
98 Down HMGA2, LIN28B, HIC2 223
125a, b Down ARID3B, LIN28b, Akt3, ETS1ARID3B, RBB2, ERBB3,TNFa, BMPR1B 223, 227, 228
126 Down SPRED1, PIK3R2, RGS4, RGS5, PI3K 229
137 Down CDK6, MITF, KLF12, PDLIM3 2
140 Down c-SRK, MMP13, FGF2 220,230
145 Down MAP3K3, MAP4K4, SOX2, OCT4, KLF4, c-myc 220, 230, 231
150 Down c-Myb, MAK9, Akt3, MAP2K4 230
184 Down TTK69, K10, Sax(A) 230
200a,b,c Down ZEB1, ZEB2, FN1, PPM1E, EXOC5, GATA4, GATA6,TUBB3, TNC, TGF-b 219 ; 232, 233
210 Down E2F3, EFNA3, HoxA1, HoxA9 226, 234, 235,236
335 Down P18SRP, HLF, CALU, MAX, HOXD8, SOX4, JAG1,TNC, c-Met, TNC 223, 228
377 Down REST, SOD1 230, 237
517a, b Down CREAP-1, MAPKAPK5, NFKBIE, PTK2B 238
519a, d,e Down FLJ31818, TGFBR2, HuR, EIF2C1, ARID4B,GATA2BD, SUV39H1 223,238, 239
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miRNA(s)
Expression
(Up/
downregulat
ed)
Estimated target(s) References
551a Down LPHN1, ERBB4, ZFP36 223
662 Down NEGR1, MKX, CSF3 223
10a,b Up USF2, HOXA1, HOXD10, HOXB1, HOXB3, RB1CC1and ribosomal proteins (enhances translation)
223,237,238,
240
21 Up PDCD4, RPS7, NCAPG, TPM1, PTEN 222, 224, 228,229, 238, 240
26a,b Up PTEN, IL6, KPNA6, CTDSPL, ITGA5, EZH2 230,237,238
27a Up ZBTB10, Myt-1, HMGB2, HOXA2, CYP1B1 226, 242
30a-5p, 30e-5p Up Unknown 223
99a,b Up SLC6A7, AIFM2, DNPEP, HS3ST2, DOHH 223, 229
130a Up MCSF, GAX, HOXA5 243, 244
141 Up ZEB1, ZEB2 245
146a Up BRCA1, BRCA2 246
181a,b Up HOXA11, GATA6, NLK, CDX2, TBL1X, DPP6,KLF2 238, 247, 248
182 Up FoxO3, FoxO1 238, 244, 249
200a Up ZEB1, ZEB2 245
200c Up TUBB3, ZEB1, ZEB2 245, 250
203 Up p63, SOCS-3, ABL1, MCEF, ADAMTS6 220, 238
205 Up ZEB1, ZEB2, E2F1, ERBB3, PKCe, SHIP2 220, 238,251
213 Up APP, SATB2 252
214 Up SLC2AB, KSR1, JMJD2B, EZH1, PLXNB3, NARG1,PTEN 226, 244
221 Up CDKN1B (p27), CDKN1C (p57) 223, 235
222 Up CDKN1B (p27), CDKN1C (p57) 253
223 Up SEPT6, MMP9, USF2, KRAS, EGF 224,237, 254
296 Up LYPLA2, IQSEC2, RNF44, HGS 223, 255
340 Up PAM, RTN3, PPL, RNF34, ZNF513 252
451 Up ZBTB10, Myt-1, HMGB2, HOXA2, CYP1B1 226, 242
494, 594 Up Unknown 223
520f Up ZNF443, AK2, NFYA,TCERG1 247
605 Up VGLL3, PHACTR2, SCAMP1, SEC24D 223, 256
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miRNA(s)
Expression
(Up/
downregulat
ed)
Estimated target(s) References
En
do
me
tria
l ca
nce
r
1 Down c-Met, TIMP-3, TRIM2, ITGB3, ZNF264 257, 258
Let-7 Down KRAS, c-Myc, HMG2A, IL-6, HIC2 229
26 Down SMAD1, SOX2, Bcl6, SMAD4, BCL2,KLF4 229
29b Down IGF1, Mcl-1 257
30c Down MYH11, GPRASP2, DDR2, CKS2,C5 250
34b,c Down NOTCH, BCL2, CCND1, WNT3, MYC, SIRT1 257, 259
101 Down COX2, EZH2 257
125 Down LIN28, ERBB2, ERBB3, Akt3 and ETS1 229
129-2 Down SOX4 192
133a,b Down PKM2, Mcl-1,Bcl2l2 257
136 Down Rtl1 257
152 Down ENPP2, SNCAIP, LTBP4, MLH1,Bcl2l11 259, 260
193a,b Down KIT, RAMP1, TSPYL5, ERBB4, ROBO4, UPA 250, 261
204 Down Ezrin, ESR1, CHD5, CAMTA1 261
221 Down LMOD, p27Kip1, p57Kip2, c-Kit 260
376a,c Down PRPS1, BMPR2, KLF15,GRIK2 257, 262
377 Down ETS1, XIAP, RNF38 257
379 Down FOXP2, MTMR2, HLCS,CCNB1 257
411 Down MAP3K1, SP2, CDH2, FOXO1, SMAD4,SET 257
424 Down CCNE1, CCND1,NFI-A 257
455-5p Down PP1R12A, KDR, SUZ12, FOXN3,PTPRJ 257, 263
518c Down ID-1, HOXA3,HOXC8,RAP1B,ABCG2,HLA-G 245,257
542-3p,5p Down COX-2, HSPG2, ZNF618, CREB5 257, 264
654-3p Down KLF12, SORBS1, WDR26, RNF145, AP1S3 229, 265
765 Down KLK4, POU2F2, TIMP3, ADAM19, BCL6B 257
873 Down FOXK2, TBL1X, TMOD2, BMPR2, SFRS1 257
1226 Down MARCH9, PPFIBP1 257
10a Up USF2, HOXA1, HOXD10, HOXB1, HOXB3, RB1CC1and ribosomal proteins 250
31 Up FOXCP2, FOXP3 261
96 Up CHES1, FOXO1, FOXO3A 261, 266
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miRNA(s)
Expression
(Up/
downregulat
ed)
Estimated target(s) References
103 Up GPD1, cdc5A, cdk6, cyclin D2, ENPP2, TIMP3 260, 268
106a Up TGFB1I1, CNN1, OLFML2A, Rbp1-like, FOXA1,KIF1A, ZIC1 257, 260
107 Up ENPP2, CDK2, HIF1a 267
142-5p Up E2F7, EGR3, IGF1, SOX11, SOX5, TGFBR2 257
155 Up UBE2J1, DCAF7, RAB34, SH3BP4 261
181a Up GPRASP1, TBL1X, DPP6, KLF2, HOXA11, GATA6,NLK, CDX2 260, 268
182, 183 Up FOXO1, FOXO3, CASP3, CASP2, Fas 257, 260, 261,266, 268
196a Up ANXA1, HOXB8, HOXA7, HOXC8, HOXD8 269
200c Up TUBB3 250
203 Up JPH4, ZIC1, CDK6, ABCE1, SMYD3, p63 257, 268
205 Up E2F1, ERBB3, JPH4, S100A2, ZEB1, ZEB2 257, 268
210 Up DCHS1, ENPP2, MYH11, KCNMB1, MNT, BDNF,PTPN1
257,260, 261,
268
363 Up CUL3, CXCL5, AGGF1, CIT, DUSP6, EPS8 261, 270
449 Up WISP2, MUC5B, EFNB1, VAMP2 261
513a-5p Up CCRL1, MCHR2, CD274, RGS5, EPS8 257
629 Up LRP6, TCF4, SEPT1, ZNF436, SLC1A7 257
Ce
rvi
cal
 ca
nce
r
Let -7b, c Down Unknown 271
29a Down Neurotrophin/TRK signaling 272, 273
26a Down Unknown 274
34a,b Down p18Ink4c, CDK4, CDK6, Cyclin E2, 2F1, E2F3, BCL2,BIRC3 199, 275
99a Down IGF-1, BCL2L2, VEGFA CDK6 274
124 Down IGFBP7, CDK6 276
138 Down hTERT 277
145 Down IGF-1 274
149,196b Down Unknown 271, 278
205 Down ZEB1, ZEB2, SIP1 279
214 Down MEK3, JNK1 175
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miRNA(s)
Expression
(Up/
downregulat
ed)
Estimated target(s) References
218 Down LAMB3 280
372 Down CDK2, Cyclin A1 281
513 Down IGF-1, BCL2L2, VEGFA CDK6 274
519a Down HuR 282
9 Up Unknown 283
10a Up (HOX) genes 274
21 Up PTEN,TPM1, PDCD4 271, 284
27a Up Unknown 285
100 Up PLK1 286
126, 127 Up Unknown 278, 287
132 Up (HOX) genes 274
133a Up Unknown 278
133b Up MST2,CDC42, RHOA,MAPK1,AKT1 288
146a Up Unknown 285
148a Up PTEN, P53INP1 and TP53INP2 274
155 Up Unknown 272, 278
182, 199b Up Unknown 278, 280
200a Up MYH10, ZEB1, DCP2, YWHAG, KIDINS220, ZEB2,TGFB2, RANBP5, EXOC5 283
203 Up p63 136
205, 221 Up Unknown 272, 285
302b, 522 Up Unknown 274
886-5p Up BAX 289
Vu
lva
r c
an
cer
19b-1-5p; 22-5p; 26b-3p;
29c-5p; 106b-3p; 142-3p;
144-5p; 151a-5p; 193a-5p;
342-3p; 365a-3p; 519b-3p;
1291
Down Unknown 72
16-5p; 21-5p; 29c-5p; 142-3p;
186-5p; 454-3p; 708-5p; 1267 Up Unknown 72
Table 2. Dysregulated miRNAs in gynecological cancer.
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Specific biological functions affected by histone modifications in gynecological cancers are
presented in Table 3.
Genes Functions Expression Up/downregulate References
Ov
ari
an
 ca
nce
r
EZH2 Lysine methyltransferase; Transcription regulator that actsin gene silencing and embryonic development; Up 290
SMYD2
(KMT3C)
Lysine methyltransferases; methylates both histones and
nonhistone proteins, including p53/TP53 and RB1. Up 291
KDM4A
A demethylase that binds to androgen receptor and
represses transcription; may play a role in regulation of cell
cycle
Up 292
EP300 Histone acetyltransferase that regulates transcription viachromatin remodeling Down 293
hMOF (KAT8) Histone acetyltransferase which may be involved intranscriptional activation. Down 294, 295
CREBBP
(KAT3A)
Plays critical roles in embryonic development, growth
control, and homeostasis by coupling chromatin remodeling
to transcription factor recognition.
Down 296
En
do
me
tria
l ca
nce
r HDAC1
Histone deacetylase 1, a transcriptional regulator that
mediates histone deacetylation, antiapoptosis, synapse
maturation, and hippocampus development
Up 297
KDM4A
A demethylase that binds to androgen receptor and
represses transcription; may play a role in regulation of cell
cycle
Up 298
EZH2 Transcription regulator that acts in gene silencing andembryonic development; Up 299
Ce
rvi
cal
 ca
nce
r
KDM5BHistone demethylase and transcription repressor that acts in
regulation of Notch signaling, stem cell maintenance, and cell differentiation Up 300
EZH2 Transcription regulator that acts in gene silencing andembryonic development Up 301
KDM5C A putative transcription regulator that may act in chromatinremodeling and brain development Down 302
KDM6A
Demethylates histone H3 lysine 27; induced expression by
papillomavirus E7 oncoprotein results in epigenetic
reprogramming
Up 303
KDM6B A transcription repressor that plays a role in gonad andlung development and defense response to Gram-positive Up 303
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Genes Functions Expression Up/downregulate References
bacteria, regulates histone methylation, macrophage
differentiation, and protein localization
EP300 Histone acetyltransferase and regulates transcription viachromatin remodeling Up 304
pCAF (KAT2B) Histone acetyltransferase (HAT) to promote transcriptionalactivation Up 305
HDAC1
Histone deacetylase 1; a transcriptional regulator that
mediates histone deacetylation, antiapoptosis, synapse
maturation, and hippocampus development
Up 306, 307
HDAC2
Histone deacetylase 2; a histone deacetylase and a
transcriptional corepressor that acts in chromatin
remodeling, inflammatory response, and regulation of
translation
Up 307
Table 3. Histone modifications in gynecological cancer.
3. The roles of microenvironment-mediated epigenetic perturbations in the
development of gynecological neoplasia
The complexity that governs the tumor phenotype cannot be explained only at the genetic level,
as genetic abnormalities occur with low frequency. Therefore, major attention was focused on
the study of the role of tumor microenvironment (TME) not only in tumor initiation but also in
progression and metastasis. The hypothesis of cancer cell development and proliferation only
in a conducive environment has been made by Paget since 1889 [308]. While Paget suggested
that  the  microenvironment  facilitates  or  inhibits  metastasis  through  growth-promoting/
inhibiting factors, recent research sustains that the tumor is directed into one or several possible
molecular evolution pathways by signals originating in native and/or modified microenviron‐
mental  factors  [309].  The  tumor  microenvironment  consists  of  epithelial  cells,  vascular
endothelial cells, fibroblasts and myofibroblasts, macrophages, leukocytes, and the extracellu‐
lar matrix (ECM). Together with the ECM, these nonmalignant cell types constitute the stromal
tissue of the tumor that secretes ECM components, cytokines, and growth factors involved in
tumor growth and invasion. All these components are dynamically interconnected around the
tumor. In the tumorigenesis process, studies have shown the critical role of chronic inflamma‐
tion  by  hyperexpression  of  the  inflammatory  mediators  in  the  microenvironment.  The
inflammatory microenvironment is both the result of genetic alterations in cancer cells and of
the tumor-infiltrating cells that produce inflammatory mediators [310].
While normal fibroblasts prevent tumor progression, cancer-associated fibroblasts (CAFs) that
display a different secretory pattern generate an environment that favors tumor growth and
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invasiveness. Tumor formation is characterized by changes in cell behavior, like accelerated
growth with loss of tissue architecture and epithelial dysfunction, angiogenesis, stromal
activation, and migratory and invasive features. Therefore, dysfunction in the tumor micro‐
environment, in addition to epithelial dysfunction, is crucial for carcinogenesis as altering its
components leads to impaired immune response. TME promotes tumorigenesis through new
blood vessel formation. Although studies have suggested that some cells in TME contained
mutations, recent data pointed, first, to the presence of mutations only in tumorigenic cells
and second, to the contribution of these mutations to epigenetic changes in both nontumori‐
genic cells and TME. In turn, the cells in the microenvironment produce epigenetic changes in
tumor cells reflected in their pattern of differentiation [311] and animal models demonstrate
that the tumor microenvironment can induce epigenetic alterations and changes in gene
expression in tumors [312].
It was suggested that the epigenome serves as the interface between the genome and the
environment [313, 314]. The epigenetic role of TME in growth induction seems to be linked
with transforming growth factor (TGF)-β and its receptor, whose expressions are regulated
through chromatin remodeling [315], although no research on stromal fibroblasts was
performed. TGFβ pathways are involved in the oncogenesis process, acting either as tumor
suppressor or as tumor promotor, depending on TME crosstalk in the tumor microenviron‐
ment [316]. In malignant progression, epigenetic changes in the expression of 12 genes
responsive to the TME stress suggest that coordinated transcriptional response of eukaryotic
cells to microenvironment might be correlated with chemotherapy resistance of solid tumors
[317]. Since tumor development is lead by physiological responses to an aberrant stromal
environment, the interaction between the tumor and stromal cells determines tumoral
progression [318]. In the chemokine network, epigenetic silencing of CXCR4 in SDF-1α/CXCR4
signaling of tumor microenvironment of cervical cancer cell lines and primary biopsy samples
limited the cell response to the paracrine source of SDF-1α, which lead to loss of cell adhesion
and disease progression [319]. Other authors reported miRNA’s contribution to cancer
progression and metastasis. While extracellular miRNAs are involved in cell–cell communi‐
cation and stromal remodeling [320], specific intracellular ones lead to cell proliferation
through cancer-associated fibroblast activation [321].
The acquisition of invasive properties in tumor cells seems to be partially linked to epithelial-
mesenchymal transition by abrogation of homotypic cell–cell adhesion due to the absence of
E-cadherin expression. Starting from the important role of transient E-cadherin expression in
neoplasia, DesRoches and collaborators investigated its regulation by the microenvironment.
Using 3D human tissue constructs, the authors suggested the role of epigenetic changes (DNA
methylation, chromatin remodeling, and specific miRNA regulation) in the plasticity of E-
cadherin-mediated adhesion in different tissue microenvironments during tumor cell invasion
and metastasis [322]. The entry of the epithelial cells into the stroma is promoted through the
E-cadherin intercellular junction disruption by MMP-3 and break down of the ECM collagen
fibers by MMP-2 and MMP-9 [323]. MicroRNA suppression also influences the changes
involved in epithelial–mesenchymal transition [324]. Reexpression of E-cadherin might
reestablish cell–cell adhesion and may result in a mesenchymal–epithelial transition that might
lead to proliferative growth of metastases.
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Metastasis, as a multistage process (tumor cell migration from primary tumor, invasion of the
surrounding tissues, intravasation into the circulation or the lymphatic system metastasis)
involves communication with surrounding nonneoplastic cells [325] that can be epigenetically
modulated to lead to ECM remodeling. Also, the epigenetic changes in the microenvironment
have a significant impact on distant metastasis. In order to create a favorable local environment
for cell proliferation in the metastatic sites, carcinoma cells induce epigenetic changes in both
the stromal cells and bone marrow–derived cells [326]. The bone marrow cells are mobilized
by the primary tumors to the metastatic sites before the actual metastasis creating a suitable
microenvironment for metastasis [315, 327].
Due to their reversal character, epigenetic changes of TME might be targeted for controlling
diseases and for therapeutic approach as drug resistance seems to also depend on TME. But,
chemotherapeutic drug resistance depends at least partly on the TME rather than the tumor
itself [328] and the combined treatment of both the tumor and the TME may be more efficient
in the fight with cancer [315].
4. Molecular and epigenetic factors involved in drug resistance
Chemotherapy success is challenged by a multitude of intrinsic or acquired, molecular, genetic
and epigenetic factors involved in drug transport, detoxification, signal transduction, gene
expression, DNA repair, and programmed cell death. Drug resistance is a major challenge that
chemotherapy should overcome. Even if the drug itself is efficient in destroying cancer cells,
it is much more complicated to avoid triggering resistance than might appear at different levels
of interaction between the drug and its cellular components.
The efflux mechanism is considered to be mainly responsible for the multiple drug resistance
phenotypes in gynecologic cancers as well as in all types of cancers [329]. The process may be
managed by cancer cells at the genetic and/or epigenetic level. While the genetic modifications
of MDR1 and related multidrug resistance proteins were intensely explored over the past few
decades, the contribution of epigenetic modification to the expression of MDR1 remains
insufficiently explored in human gynecological cancers. It was observed that MDR1 was
hypermethylated in 100% of ovarian cancer cell lines, and in 5 out of 13 (38%) primary ovarian
cancers associated with loss of MDR1 mRNA expression in ovarian cancer cell lines, sustaining
the importance role of epigenetic regulation in the expression of MDR1 and clinical treatment
outcomes in human ovarian cancer [330]. However, in six ovarian cancer cell lines—W1MR,
W1CR, W1DR, W1VR, W1TR, and W1PR that are respectively resistant to methotrexate,
cisplatin, doxorubicin, vincristine, topotecan, and paclitaxel, P-gp is responsible for chemore‐
sistance and, in the case of methotrexate, was found to have a relation between the MRP2
transcript level and drug resistance [331]. Among inhibitors of Pgp MDR, valspodar, an analog
of cyclosporine A, showed no clinical benefit in a phase III trial with paclitaxel and carboplatin
[332], because while these agents can block drug efflux at the cellular level, the effects are not
tumor specific, requiring a reduction in dosage for minimizing the side effects but also the
therapeutic advantage. On the other hand, miRNA was involved in resistance through the
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regulation of MDR proteins at a posttranscriptional level. The interaction of miRNAs with the
targeted mRNA can downmodulate MDR proteins improving the response to anticancer
drugs. It was described [329] that miR-223 can downregulate ABCB1 and mRNA levels.
miR-124a and miR-506 significantly decreased the protein level of MRP4 (ABCC4), which is
another efflux membrane transporter; however, these miRNAs did not change the gene
transcription levels [333]. In addition, although there are many modalities acting on efflux
proteins in order to circumvent drug resistance, their effective action can be compromised due
to the diversity of signal transduction pathways involved in transporter-mediated MDR, such
as MAPK, JNK, PI3K, among others; as well as some transcription factors, like NF-κB, TNF-
α, and PTEN that could influence the levels of carrier proteins in different conditions [334].
Also, the signal transduction pathways can be involved in drug resistance. The Wnt signaling
pathway, which is regulated by a multiprotein complex consisting of, among others, members
of β-catenin, adenomatous polyposis coli APC, Axin, and GSK-3β [335], are involved in
calcium-dependent cell adhesion due to the interaction between β-catenin and cadherin [336].
Different mutations in APC, promotes β-catenin proteolysis and reduces its transcriptional
activity. PTEN, a lipid and protein phosphatase that is a negative regulator of phosphatidyli‐
nositol 3 (PI-3) kinase-dependent signaling interacts with the WNT pathway by impeding
activation of integrin-linked kinase (ILK), which inhibits GSK-3β and thus causes accumula‐
tion of β-catenin [337]. The WNT signaling pathway is the most frequently altered pathway in
the majority of cancers; therefore, individual components of the pathway are interesting targets
for epigenetic inactivation. PI3K/Akt is another signaling pathway that is involved in acquired
resistance of many cancers including gynecological ones. All of its isoforms (Akt1, Akt2, and
Akt3) are activated (phosphorylated) by phosphatidylinositol 3-kinase (PI3-K) in response to
growth factors and promote cell survival. It was demonstrated that the Akt pathway is directly
related to the resistance of cancers against different drugs like sorafenib, trastuzumab, and
erlotinib [329]. The epigenetic control of Akt and NF-κB is important for the establishment of
drug resistance. RUNX3 suppresses Akt1 transcription by directly binding to the Akt1
promoter, and methylation of RUNX3 induces activation of the Akt signaling pathway [329].
Acquired resistance may develop additionally as blockage of apoptotic pathways or defective
apoptotic signaling, often associated with loss of tumor suppressor protein p53, but also
independent of p53, alteration of the control points of the cell cycle, increased ability to repair
DNA, increased DNA damage tolerance, oncogene induction, and downmodulation of tumor
suppressor genes. Eluding the normal process of programmed cell death is already known as
a crucial strategy for cancer development and progression, but even more importantly, its
participation in the intrinsic or acquired resistance of cancer cells to chemotherapy and
radiation. Identification of the points of therapeutic intervention could potentially open up
more efficient treatment opportunities. Epigenetic strategies might also be a feasible strategy
to reactivate apoptosis or on the contrary to inactivate apoptosis-related genes that inhibit the
process. However, it has now been demonstrated that inhibitors of DNA methylation and
histone deacetylases can reactivate expression of tumor suppressor genes and induce histone
hyperacetylation in the tumors of patients with cervical cancer after treatment with these
agents. Preclinical studies have suggested a multitude of strategies to prevent or overcome
resistance, but these approaches have not successfully translated to clinical practice yet [338].
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5. Conclusions
This chapter underlined the importance of epigenetic events in gynecological cancer. Deci‐
phering the relevant epigenetic changes associated with each step of tumor development might
improve molecular diagnostic and cancer risk assessment. Advances in elucidating epigenetic
regulation in cancer disease, as well as in the development of technology, lead to the identifi‐
cation of potential biomarkers for diagnostic screening. As epigenetic changes occur early in
neoplastic process, epigenetic biomarkers seem to be more sensitive and specific in cancer
detection and some have already been tested for several types of cancer, alone or in combina‐
tion with traditional biomarkers. Unlike genetic changes, epigenetic alterations are essentially
reversible and allow plasticity. These features are exploited and new therapeutic agents
targeting epigenetic processes have been developed. The epigenetic changes of the trans‐
formed cells or TME can be modified by chemotherapeutic drugs and this epigenetic reversal
therapy has potential in the future. In addition, miRNAs should be heavily explored as they
might represent future alternatives for combined therapy of cancer. Many epigenetic targets
are druggable and in order to overcome drug resistance, epigenetic therapy might also be a
feasible strategy for induced cell death. Moreover, epigenetic patterns might be useful tools
for therapy response prediction.
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